Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129


Influence of a low dose of amphetamine on vesicular monoamine transporter binding: a PET (+)[11C]DTBZ study in humans.

Boileau I, Houle S, Rusjan PM, Furukawa Y, Wilkins D, Tong J, Selby P, Wilson AA, Kish SJ.

Synapse. 2010 Jun;64(6):417-20. doi: 10.1002/syn.20743.


Increased vesicular monoamine transporter binding during early abstinence in human methamphetamine users: Is VMAT2 a stable dopamine neuron biomarker?

Boileau I, Rusjan P, Houle S, Wilkins D, Tong J, Selby P, Guttman M, Saint-Cyr JA, Wilson AA, Kish SJ.

J Neurosci. 2008 Sep 24;28(39):9850-6. doi: 10.1523/JNEUROSCI.3008-08.2008.


Dopamine modulating drugs influence striatal (+)-[11C]DTBZ binding in rats: VMAT2 binding is sensitive to changes in vesicular dopamine concentration.

Tong J, Wilson AA, Boileau I, Houle S, Kish SJ.

Synapse. 2008 Nov;62(11):873-6. doi: 10.1002/syn.20573.


Striatal [11C]dihydrotetrabenazine and [11C]methylphenidate binding in Tourette syndrome.

Albin RL, Koeppe RA, Wernette K, Zhuang W, Nichols T, Kilbourn MR, Frey KA.

Neurology. 2009 Apr 21;72(16):1390-6. doi: 10.1212/WNL.0b013e3181a187dd.


Decreased vesicular monoamine transporter type 2 availability in the striatum following chronic cocaine self-administration in nonhuman primates.

Narendran R, Jedema HP, Lopresti BJ, Mason NS, Himes ML, Bradberry CW.

Biol Psychiatry. 2015 Mar 1;77(5):488-92. doi: 10.1016/j.biopsych.2014.06.012. Epub 2014 Jun 23.


A rapid oxidation and persistent decrease in the vesicular monoamine transporter 2 after methamphetamine.

Eyerman DJ, Yamamoto BK.

J Neurochem. 2007 Nov;103(3):1219-27. Epub 2007 Aug 7.


In vivo evidence for low striatal vesicular monoamine transporter 2 (VMAT2) availability in cocaine abusers.

Narendran R, Lopresti BJ, Martinez D, Mason NS, Himes M, May MA, Daley DC, Price JC, Mathis CA, Frankle WG.

Am J Psychiatry. 2012 Jan;169(1):55-63. doi: 10.1176/appi.ajp.2011.11010126. Epub 2011 Oct 31.


Synthesis and biological evaluation of 10-(11) C-dihydrotetrabenazine as a vesicular monoamine transporter 2 radioligand.

Li X, Chen Z, Tang J, Liu C, Zou P, Huang H, Tan C, Yu H.

Arch Pharm (Weinheim). 2014 May;347(5):313-9. doi: 10.1002/ardp.201300307. Epub 2014 Feb 3.


A Novel Potential Positron Emission Tomography Imaging Agent for Vesicular Monoamine Transporter Type 2.

Huang ZR, Tsai CL, Huang YY, Shiue CY, Tzen KY, Yen RF, Hsin LW.

PLoS One. 2016 Sep 9;11(9):e0161295. doi: 10.1371/journal.pone.0161295. eCollection 2016.


Fluoroalkyl derivatives of dihydrotetrabenazine as positron emission tomography imaging agents targeting vesicular monoamine transporters.

Goswami R, Ponde DE, Kung MP, Hou C, Kilbourn MR, Kung HF.

Nucl Med Biol. 2006 Aug;33(6):685-94.


Assessment of extrastriatal vesicular monoamine transporter binding site density using stereoisomers of [11C]dihydrotetrabenazine.

Koeppe RA, Frey KA, Kuhl DE, Kilbourn MR.

J Cereb Blood Flow Metab. 1999 Dec;19(12):1376-84.


Rapid Recovery of Vesicular Dopamine Levels in Methamphetamine Users in Early Abstinence.

Boileau I, McCluskey T, Tong J, Furukawa Y, Houle S, Kish SJ.

Neuropsychopharmacology. 2016 Mar;41(4):1179-87. doi: 10.1038/npp.2015.267. Epub 2015 Aug 31.


Presynaptic control of striatal dopamine neurotransmission in adult vesicular monoamine transporter 2 (VMAT2) mutant mice.

Patel J, Mooslehner KA, Chan PM, Emson PC, Stamford JA.

J Neurochem. 2003 May;85(4):898-910.


VMAT2 binding is elevated in dopa-responsive dystonia: visualizing empty vesicles by PET.

De La Fuente-Fernández R, Furtado S, Guttman M, Furukawa Y, Lee CS, Calne DB, Ruth TJ, Stoessl AJ.

Synapse. 2003 Jul;49(1):20-8.


Quantitative analysis of the therapeutic effect of magnolol on MPTP-induced mouse model of Parkinson's disease using in vivo 18F-9-fluoropropyl-(+)-dihydrotetrabenazine PET imaging.

Weng CC, Chen ZA, Chao KT, Ee TW, Lin KJ, Chan MH, Hsiao IT, Yen TC, Kung MP, Hsu CH, Wey SP.

PLoS One. 2017 Mar 3;12(3):e0173503. doi: 10.1371/journal.pone.0173503. eCollection 2017.


Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers.

Johanson CE, Frey KA, Lundahl LH, Keenan P, Lockhart N, Roll J, Galloway GP, Koeppe RA, Kilbourn MR, Robbins T, Schuster CR.

Psychopharmacology (Berl). 2006 Apr;185(3):327-38. Epub 2006 Mar 3. Erratum in: Psychopharmacology (Berl). 2006 Jul;186(4):620.


In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease.

Lee CS, Samii A, Sossi V, Ruth TJ, Schulzer M, Holden JE, Wudel J, Pal PK, de la Fuente-Fernandez R, Calne DB, Stoessl AJ.

Ann Neurol. 2000 Apr;47(4):493-503.


Supplemental Content

Support Center